Healthy Prospects: Growth Sectors, New Products and Strong Marketing - Research Report on Boston Scientific, Thermo Fisher,

    Healthy Prospects: Growth Sectors, New Products and Strong Marketing -
Research Report on Boston Scientific, Thermo Fisher, Volcano, Align Technology
                                 and Accuray

PR Newswire

NEW YORK, March 8, 2013

NEW YORK, March 8, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Boston
Scientific Corporation (NYSE: BSX), Thermo Fisher Scientific Inc. (NYSE: TMO),
Volcano Corporation (NASDAQ: VOLC), Align Technology, Inc. (NASDAQ: ALGN) and
Accuray Incorporated (NASDAQ: ARAY). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Boston Scientific Corporation Research Report

Boston Scientific is scheduled to present PREVAIL clinical trial results on
March 9, 2013 at the American College of Cardiology 2013 Annual Scientific
Sessions. The study was designed to see if the company's WATCHMAN device could
effectively prevent strokes. The WATCHMAN has already been available for sale
in Europe since 2005 and some countries in Asia since 2009. In the United
States, however, WATCHMAN is still an investigational device, and results from
the PREVAIL confirmatory study are expected to be submitted for approval to
the US FDA. WATCHMAN is a highly promising device for Boston Scientific, with
Wells Fargo analyst Biegelsen projecting its sales to total at $159 by 2017.
Going forward, Boston Scientific plans on outpacing its rivals and boost its
business in high growth markets like endoscopy, urology, and women's health.
The Full Research Report on Boston Scientific Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/b465_BSX]

--

Thermo Fisher Scientific Inc. Research Report

Thermo Fischer recently launched the Brilliance GBS Agar for the testing of
Group B streptococci (GBS) during pregnancy. The new product is designed to
simplify screening tests for clinicians and produce more accurate results. GBS
is a bacterium that can be passed from mother to baby during labor, and is the
most common cause of severe, sometimes fatal, infections. The product is
designed for laboratories that are already screening for GBS but are looking
for more efficient ways to produce results. Going forward, Thermo Fisher plans
to continue investing in new products and emerging markets to drive growth.
The company's One Lambda acquisition may also accelerate its growth in the
transplant diagnostics market. The Full Research Report on Thermo Fisher
Scientific Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/ce54_TMO]

--

Volcano Corporation Research Report

Volcano Corporation recently reported record fourth quarter revenue of $102.5
million, up 10 percent on a reported basis and up 12 percent on a constant
currency basis. The company cites strength in its Fractional Flow Reserve
disposable business as the reason for this increase. Going forward, the
company's acquisitions of Sync-RX and Crux Biomedical are expected to help the
company move beyond intravascular imaging to a wide variety of diagnostic and
therapeutic solutions for both coronary and peripheral applications. These
business expansion strategies may drive growth for the company. Furthermore,
the company's market-leading position in Japan remains encouraging. The Full
Research Report on Volcano Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investors-alliance.com/r/full_research_report/6ba1_VOLC]

--

Align Technology, Inc. Research Report

Last year, Align Technology's Invisalign Clear Aligner proved its worth, with
Invisalign Clear Aligner case shipments totaling 365.5 thousand, up 17.5
percent year-over-year. This year, the company is working to push Invisalign's
potential further. By appointing Julie Tay as Vice President for its Asia
Pacific operations, the company may now execute its strategy of moving its
four largest country markets (Australia, New Zealand, Hong Kong and Singapore)
from an indirect selling business model to a direct selling business model.
Align Technology recognizes that Asia Pacific may provide significant growth
opportunities for the company, and this effort may help it to further
accelerate its growth in the region. Seeing the company's positive momentum,
analysts at Stifel Nicolaus raised their price target on the shares of the
company from $32 to $38 and maintained their Buy rating. The Full Research
Report on Align Technology, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/9b76_ALGN]

--

Accuray Incorporated Research Report

At present, Accuray is setting up a cost structure that will enhance marketing
capabilities and overall business processes to boost sales. The company's two
new products, the CyberKnife and TomoTherapy devices, are the ones that are
expected to benefit from this strategy. The company is also reducing its
operating expenses to achieve sustainable profitability. To signal his
confidence in the company, President and CEO of Accuray Inc. Joshua Levine
recently bought 100,000 shares of Accuray Incorporated. Accuray's efforts to
market its most valuable products may drive sales and allow the company to
generate greater revenue in the future. The Full Research Report on Accuray
Incorporated - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/cb33_ARAY]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance